scholarly journals Salivary Cytomegalovirus (CMV) Shedding, Glycoprotein B Genotype Distribution, and CMV Disease in Human Immunodeficiency Virus–Seropositive Patients

2001 ◽  
Vol 33 (8) ◽  
pp. 1406-1411 ◽  
Author(s):  
N. Fidouh‐Houhou ◽  
X. Duval ◽  
F. Bissuel ◽  
V. Bourbonneux ◽  
P. Flandre ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Glycoprotein B ◽  
Genotype Distribution ◽  
Immunodeficiency Virus ◽  
Cmv Disease

scholarly journals Cytomegalovirus Glycoprotein B Groups in Human Immunodeficiency Virus–Infected Patients with Incident Retinitis

2002 ◽  
Vol 186 (1) ◽  
pp. 114-117 ◽  
Author(s):  
W. Lawrence Drew ◽  
Sunwen Chou ◽  
Richard C. Miner ◽  
Beth A. Mohr ◽  
Michael P. Busch ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Glycoprotein B ◽  
Immunodeficiency Virus

scholarly journals The genotype distribution, infection stage and drug resistance mutation profile of human immunodeficiency virus-1 among the infected blood donors from five Chinese blood centers, 2014–2017

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243650
Author(s):  
Shan Liang ◽  
Zhiyang Liu ◽  
Shaoli Wang ◽  
Jing Liu ◽  
Ling Shi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Blood Donors ◽  
Resistance Mutation ◽  
Genotype Distribution ◽  
Significant Difference ◽  
Immunodeficiency Virus ◽  
Rt Inhibitors ◽  
Hiv 1 ◽  
Human Immunodeficiency Virus 1

Human immunodeficiency virus-1 (HIV-1) exhibits high diversity and complexity in China, challenging the disease surveillance and antiretroviral therapy. Between July 1, 2014 and January 30, 2017, we investigated the profiles of HIV-1 infection stages, genotype distribution and drug resistance mutations (DRMs) using plasma samples from HIV Western blot (WB) confirmed blood donors from five Chinese blood centers (Chongqing, Guangxi, Luoyang, Mianyang, and Urumqi). HIV pol regions consisted of whole protease and partial reverse transcriptase were genotyped and analyzed for DRMs. Lag-Avidity testing was performed to identify the infection stages. Of the 356 HIV-1 WB positive samples tested by Lag-avidity assay, 19.1% (68/356) were recent infections. Genotyping on 356 amplified sequences presented the subtype distributions as following: CRF07_BC (65.7%), CRF08_BC (7.3%), CRF01_AE (19.1%), B (4.2%), CRF55_01B (3.1%), CRF59_01B (0.3%) and CRF68_01B (0.3%). No significant difference in genotype distribution was observed between recent and long-term infections. 48 DRMs were identified from 43 samples, indicating a drug resistance prevalence of 12.1% (43/356), which include seven protease inhibitors (PIs) accessory DRMs (Q58E, L23I and I84M), two PIs major DRMs (M46I, M46L), seven nucleoside RT inhibitors DRMs (D67N, K70Q, K219R and M184L), and 32 non-nucleoside RT inhibitors DRMs (K103N, V179E, K238N, V179D, E138G, G190E, A98G, Y188D and E138A). In addition, we had also identified CRFs from the 01B subtype including CRF55_01B (3.1%), CRF59_01B (0.3%) and CRF68_01B (0.3%). As an important part of the continuous monitoring of HIV-1 circulating strains among blood donors, our findings were expected to contribute to the comprehensive AIDS control and development of proper diagnostics for HIV-1 in China.

scholarly journals Evaluation of New Quantitative Assays for Diagnosis and Monitoring of Cytomegalovirus Disease in Human Immunodeficiency Virus-Positive Patients

1999 ◽  
Vol 37 (10) ◽  
pp. 3124-3132 ◽  
Author(s):  
Isabelle Pellegrin ◽  
Isabelle Garrigue ◽  
Christine Binquet ◽  
Genevieve Chene ◽  
Didier Neau ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Disease Diagnosis ◽  
Blood Leukocytes ◽  
Predictive Values ◽  
Immunodeficiency Virus ◽  
Antigenemia Assay ◽  
Pp65 Antigenemia ◽  
Quantitative Results ◽  
Sensitivity Specificity ◽  
Cmv Disease

Cobas Amplicor CMV Monitor (CMM) and Quantiplex CMV bDNA 2.0 (CMV bDNA 2.0), two new standardized and quantitative assays for the detection of cytomegalovirus (CMV) DNA in plasma and peripheral blood leukocytes (PBLs), respectively, were compared to the CMV viremia assay, pp65 antigenemia assay, and the Amplicor CMV test (P-AMP). The CMV loads were measured in 384 samples from 58 human immunodeficiency virus (HIV) type 1-infected, CMV-seropositive subjects, including 13 with symptomatic CMV disease. The assays were highly concordant (agreement, 0.88 to 0.97) except when the CMV load was low. Quantitative results for plasma and PBLs were significantly correlated (Spearman ρ = 0.92). For PBLs, positive results were obtained 125 days before symptomatic CMV disease by CMV bDNA 2.0 and 124 days by pp65 antigenemia assay, whereas they were obtained 46 days before symptomatic CMV disease by CMM and P-AMP. At the time of CMV disease diagnosis, the sensitivity, specificity, and positive and negative predictive values of CMV bDNA 2.0 were 92.3, 97.8, 92.3, and 97.8%, respectively, whereas they were 92.3, 93.3, 80, and 97.8%, respectively, for the pp65 antigenemia assay; 84.6, 100, 100, and 95.7%, respectively, for CMM; and 76.9, 100, 100, and 93.8%, respectively, for P-AMP. Considering the entire follow-up, the sensitivity, specificity, and positive and negative predictive values of CMV bDNA 2.0 were 92.3, 73.3, 52.1, and 97.1%, respectively, whereas they were 100, 55.5, 39.4, and 100%, respectively, for the pp65 antigenemia assay; 92.3, 86.7, 66.7, and 97.5%, respectively, for CMM; and 84.6, 91.1, 73.3, and 95.3%, respectively, for P-AMP. Detection of CMV in plasma is technically easy and, despite its later positivity (i.e., later than in PBLs), can provide enough information sufficiently early so that HIV-infected patients can be effectively treated. In addition, these standardized quantitative assays accurately monitor the efficacy of anti-CMV treatment.

Sign in / Sign up

Export Citation Format

Share Document